Irene M. Ghobrial, MD, on How COVID-19 is Changing the Conduct of Clinical Trials
COVID-19 and Cancer Care
Irene M. Ghobrial, MD, of Dana-Farber Cancer Institute, talks about PROMISE—her screening study for people at high-risk of developing precursor conditions of multiple myeloma—and how this and other trials have been altered in the wake of the pandemic, as well as what might be considered a silver lining to the crisis. Filmed March 30, 2020.
The ASCO Post Staff
How have the activities of the Center for International Blood and Marrow Transplant Research been affected by the COVID-19 pandemic?
Recorded April 21, 2020.
The ASCO Post Staff
Syed A. Abutalib, MD, of Cancer Treatment Centers of America, talks with Miguel-Angel Perales, MD, of Memorial Sloan Kettering Cancer Center, about the challenges and concerns related to transplants for patients with hematologic malignancies who are particularly vulnerable to infection with the coronavirus. Recorded July 13, 2020.
The ASCO Post Staff
Rafal Dziadziuszko, MD, PhD, of the Medical University of Gdansk, talks about the adjustments to cancer care that he and his colleagues have made, how and when they employ telemedicine, and whether the technology could change the future for clinical practice. Filmed April 24, 2020.
The ASCO Post Staff
Are you treating patients with advanced chronic myeloid leukemia (accelerated phase or blast crisis) any differently during the COVID-19 pandemic?
Recorded April 24, 2020.
The ASCO Post Staff
How has the COVID-19 pandemic changed your approach to the selection of tyrosine kinase inhibitors for the treatment of patients with chronic myeloid leukemia?
Recorded April 24, 2020.